Seres Therapeutics Files 8-K for Other Events
Ticker: MCRB · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.0, $1.4 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Seres Therapeutics filed an 8-K for 'Other Events' on 9/23/25. Details TBD.
AI Summary
Seres Therapeutics, Inc. filed an 8-K on October 3, 2025, reporting an event on September 23, 2025. The filing pertains to 'Other Events' and does not specify any material agreements, asset acquisitions, or executive changes. The company's principal executive offices are located at 101 Cambridgepark Drive, Cambridge, MA.
Why It Matters
This filing indicates Seres Therapeutics is reporting an event, but the lack of specific details in the provided text means its immediate impact on the company or investors is unclear without further information.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosure of significant financial or operational changes.
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Registrant
- September 23, 2025 (date) — Date of earliest event reported
- October 3, 2025 (date) — Date of Report
- 101 Cambridgepark Drive, Cambridge, MA (location) — Address of principal executive offices
FAQ
What specific event is Seres Therapeutics reporting on September 23, 2025?
The provided text for the 8-K filing indicates the event date is September 23, 2025, and the filing item is 'Other Events', but does not specify the nature of the event.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on October 3, 2025.
What is the primary business of Seres Therapeutics, Inc.?
Seres Therapeutics, Inc. is in the 'Pharmaceutical Preparations' industry, SIC code 2834.
Where are Seres Therapeutics' principal executive offices located?
The principal executive offices are located at 101 Cambridgepark Drive, Cambridge, MA 02140.
Has Seres Therapeutics changed its name previously?
Yes, the company was formerly known as Seres Health, Inc., with a name change date of June 3, 2014.
Filing Stats: 874 words · 3 min read · ~3 pages · Grade level 14.9 · Accepted 2025-10-03 16:06:43
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar
- $1.0 — result in cash charges of approximately $1.0 to $1.4 million, primarily related to s
- $1.4 m — n cash charges of approximately $1.0 to $1.4 million, primarily related to severance c
Filing Documents
- d63317d8k.htm (8-K) — 26KB
- 0001193125-25-230118.txt ( ) — 135KB
- mcrb-20250923.xsd (EX-101.SCH) — 3KB
- mcrb-20250923_lab.xml (EX-101.LAB) — 17KB
- mcrb-20250923_pre.xml (EX-101.PRE) — 11KB
- d63317d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K (this "Current Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding cost saving initiatives, including anticipated workforce reductions, restructuring charges, cash savings, operating plans and our cash runway, and the timing of any of the foregoing. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) our need for additional funding; (2) our ability to continue as a going concern; (3) we have incurred significant losses, are not currently profitable and may never become profitable; (4) our history of operating losses; (5) our cost savings initiative may not be successful, and may not have its anticipated benefits; (6) our ability to manage our recent CEO transition, to retain key personnel and to manage our growth; and the other important factors discussed under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025, and the Company's other reports filed with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management's estimates as of the date of this Current Report. While we may elect to update such forward-looki
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERES THERAPEUTICS, INC. Date: October 3, 2025 By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Co-Chief Executive Officer, Co-President, Executive Vice President, Chief Legal Officer and Secretary